BAYN.DE Stock Rises 1.6% on Perfuse Acquisition, May 7 2026

BAYN.DE stock climbed 1.6% to €38.51 in pre-market trading on May 7, 2026, as Bayer AG announced a strategic acquisition. The German pharmaceutical giant agreed to buy Perfuse Therapeutics, a San Francisco-based eye-medicine developer, for up to $2.45 billion. This move signals Bayer’s commitment to strengthening its drug pipeline amid rising generic competition. The acquisition targets specialty therapeutics in ophthalmology, a high-growth segment. Investors are watching how this deal impacts BAYN.DE stock performance and the company’s long-term profitability. The stock trades on XETRA in EUR currency, with a market cap of €37.8 billion.

BAYN.DE Stock Performance and Market Reaction

BAYN.DE stock opened at €37.80 and reached a day high of €38.87, reflecting positive sentiment around the Perfuse acquisition. The stock gained €0.61 from the previous close of €37.90, representing a 1.6% increase. Trading volume hit 2.62 million shares, below the 3.41 million average, suggesting cautious positioning ahead of earnings.

The 50-day moving average sits at €39.29, while the 200-day average stands at €34.53. This places BAYN.DE stock above its longer-term trend but slightly below recent resistance. Year-to-date, the stock has gained 1.5%, though it remains down 33.96% over three years. The acquisition announcement appears to have stabilized sentiment after recent weakness.

Perfuse Acquisition Strengthens Ophthalmology Portfolio

Bayer’s €2.45 billion acquisition of Perfuse Therapeutics represents a strategic bet on eye-medicine innovation. The deal complements Bayer’s existing specialty therapeutics in oncology, hematology, and ophthalmology, addressing gaps in its pipeline. Perfuse brings promising candidates for treating eye diseases, a market with significant growth potential.

This acquisition aligns with Bayer’s three-segment strategy: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment, which includes specialty therapeutics, generated strong revenue despite margin pressures. By acquiring Perfuse, Bayer gains access to novel compounds and reduces reliance on aging blockbuster drugs facing generic erosion.

Financial Metrics and Valuation Concerns

BAYN.DE stock trades at a negative P/E ratio of -10.45, reflecting recent net losses. The company reported negative earnings per share of -€3.68 trailing twelve months. However, the price-to-sales ratio of 0.83 suggests the stock trades at a discount to revenue, indicating potential value.

Key metrics show mixed signals: operating cash flow per share reached €5.51, while free cash flow per share was €2.98. The debt-to-equity ratio of 1.44 indicates moderate leverage. Return on equity stands at -12.2%, pressured by net losses. Track BAYN.DE on Meyka for real-time updates on these financial developments and quarterly results.

Earnings Announcement and Forward Outlook

Bayer is scheduled to report earnings on May 12, 2026, at 3:30 PM UTC. This timing makes the Perfuse acquisition announcement particularly strategic, as management can discuss integration plans during the earnings call. Analysts will scrutinize guidance on cost synergies and timeline for profitability improvements.

The company faces headwinds from generic competition and litigation costs, but the acquisition signals confidence in long-term growth. Revenue growth turned negative at -2.2% year-over-year, while operating income surged 30.86%. This divergence suggests operational efficiency gains offsetting top-line pressure. Investors should monitor how management addresses profitability and cash generation during the earnings presentation.

Final Thoughts

BAYN.DE stock gained 1.6% to €38.51 on May 7 as Bayer AG’s €2.45 billion acquisition of Perfuse Therapeutics reinforced its pharmaceutical strategy. The deal addresses pipeline gaps in ophthalmology and specialty therapeutics, critical for competing against generic erosion. While BAYN.DE stock trades at a discount on price-to-sales metrics, negative earnings and high leverage remain concerns. The upcoming May 12 earnings call will be crucial for clarifying integration plans and profitability timelines. Investors should weigh the acquisition’s strategic merit against near-term financial headwinds before making investment decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.